Saša Dimitrijević
Blueprint Medicines (United States)(US)
Publications by Year
Research Areas
Mast cells and histamine, Gastrointestinal Tumor Research and Treatment, Chronic Myeloid Leukemia Treatments, PI3K/AKT/mTOR signaling in cancer, Eosinophilic Disorders and Syndromes
Most-Cited Works
- → Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors(2002)4,371 cited
- → Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor(2003)2,287 cited
- → Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor(2001)2,054 cited
- → Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study(2001)1,270 cited
- → Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta(2002)630 cited
- → Management of malignant gastrointestinal stromal tumours(2002)569 cited
- → Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors(2008)528 cited
- → 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)(2003)526 cited
- → Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated With Imatinib: Imatinib Target Exploration Consortium Study B2225(2005)477 cited
- → The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations(2002)447 cited